Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Envoy Medical, Inc.COCH · Entity 7161 | Director | February 12, 2026 | February 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Envoy Medical, Inc.
Report date February 12, 2026 · Filed February 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 332,500 |
Reported balance
After 2026-02-12 transaction · row 1
1 source rowRow 1 · 2026-02-12 · Purchase · Acquired 312,500 · Balance 332,500 |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 | Direct | 187,500 |
Reported balance
After 2026-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-12 · Purchase · Acquired 187,500 · Balance 187,500 F2: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F3: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 | Direct | 312,500 |
Reported balance
After 2026-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-12 · Purchase · Acquired 312,500 · Balance 312,500 F2: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F4: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2033-10-15 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 25,000 F1: Options to purchase 6,250 shares vest on 10/15/2024, and the remaining 18,750 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.81 · Expires 2035-12-03 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 25,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 6,250 shares vest on 10/15/2024, and the remaining 18,750 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
F2: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
F3: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
F4: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 17, 2026 21:51 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseWarrant (right to buy) · Derivative | 312,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000028 · form4.xml · derivative · entry 5 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,500 Underlying: Class A Common Stock · 312,500 shares Expires not disclosed F2 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F4 · derivative.expiration_date: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:51 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseWarrant (right to buy) · Derivative | 187,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000028 · form4.xml · derivative · entry 4 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,500 Underlying: Class A Common Stock · 187,500 shares Expires not disclosed F2 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F3 · derivative.expiration_date: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:51 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseClass A Common Stock | 312,500 | $0.40 | $125,000.00 |
DisclosureSEC source: 0000914190-26-000028 · form4.xml · nonDerivative · entry 1 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,500 Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 22:41 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0000914190-25-000050 · form4.xml · derivative · entry 3 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2035-12-03 Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:10 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseClass A Common Stock | 2,500 | $1.47 | $3,675.00 |
DisclosureSEC source: 0001062993-25-011661 · form4.xml · nonDerivative · entry 1 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.44 to $1.4799 inclusive. The reporting person undertakes to provide Envoy Medical, Inc., any security holder of Envoy Medical, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:11 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseClass A Common Stock | 10,000 | $1.46 | $14,600.00 |
DisclosureSEC source: 0001062993-25-011320 · form4.xml · nonDerivative · entry 1 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.42 to $1.4981 inclusive. The reporting person undertakes to provide Envoy Medical, Inc., any security holder of Envoy Medical, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:32 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseClass A Common Stock | 2,500 | $2.28 | $5,698.75 |
DisclosureSEC source: 0001062993-24-019574 · form4.xml · nonDerivative · entry 1 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Read SEC document |
| September 11, 2024 Filed Sep 11, 2024 20:50 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseClass A Common Stock | 4,000 | $3.33 | $13,320.00 |
DisclosureSEC source: 0001062993-24-016486 · form4.xml · nonDerivative · entry 2 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · price: Represents a weighted average price. These shares of Class A Common Stock were purchased in multiple transactions at prices ranging from $3.28 to $3.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:50 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseClass A Common Stock | 1,000 | $3.20 | $3,200.00 |
DisclosureSEC source: 0001062993-24-016486 · form4.xml · nonDerivative · entry 1 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| October 15, 2023 Filed Oct 17, 2023 20:11 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001062993-23-019443 · form4.xml · derivative · entry 1 Patel Mona Chetan · CIK 0001995769 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2033-10-15 F1 · derivative.exercise_date: Options to purchase 6,250 shares vest on 10/15/2024, and the remaining 18,750 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.